FactaeThe Factual News

Novartis resists generic competition with rising profits

Novartis reports rising profits for the second quarter of 2026.

Published 6sem1 sourceNotableupdated 14h
Lire en français
≈ 15s

The fact

The Swiss pharmaceutical group faces increased generic competition on its blockbusters.

Its results exceed expectations due to strict cost management.

Click the link to read an article on the topic:
Explore this topic
What if you saw the whole news differently?Factae cross-checks hundreds of sources worldwide to keep only the fact, no opinion. Explore the front page.
SuisseWorld map →
Follow topic →
Auto-synthesis from 1 media source · identified on July 21, 2026
← Back to home
Discover

Read more

All marches →
monde

Novartis revives growth despite losing patents on Entresto

6sem · 1 sourcemonde1.5 %

Swiss economy rebounds thanks to the pharmaceutical industry

2j · 1 sourcemarches

Novartis to present renal portfolio data in early June

14sem · 1 sourcemarches

Novartis highlighted at the 2026 European Society of Cardiology congress

2sem · 1 sourcemarches

Switzerland: Swiss franc hits annual low against the euro

7h · 1 sourcemarches

Novartis: experimental heart drug fails key trial

13h · 1 source